Equity Overview
Price & Market Data
Price: $0.183
Daily Change: -$0.037 / 20.22%
Daily Range: $0.183 - $0.27
Market Cap: $8,831,181
Daily Volume: 1,271,767
Performance Metrics
1 Week: 2.86%
1 Month: 39.03%
3 Months: 101.6%
6 Months: -80.24%
1 Year: -85.50%
YTD: -81.84%
Company Details
Employees: 30
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.